BG100248A - Инхибитори на скваленсинтетаза - Google Patents

Инхибитори на скваленсинтетаза

Info

Publication number
BG100248A
BG100248A BG100248A BG10024895A BG100248A BG 100248 A BG100248 A BG 100248A BG 100248 A BG100248 A BG 100248A BG 10024895 A BG10024895 A BG 10024895A BG 100248 A BG100248 A BG 100248A
Authority
BG
Bulgaria
Prior art keywords
synthetase inhibitors
squalene synthetase
squalene
inhibitors
hypochlesterolemic
Prior art date
Application number
BG100248A
Other languages
English (en)
Inventor
Ernest Hamanaka
Joel HAWKINS
Cheryl Hayward
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG100248A publication Critical patent/BG100248A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

Изобретението се отнася до бензоксазепинони и бензотиазепинони, полезни като хипохолестеролемични иантиатеросклеротични средства.
BG100248A 1994-12-23 1995-12-21 Инхибитори на скваленсинтетаза BG100248A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36271394A 1994-12-23 1994-12-23
PCT/IB1995/000424 WO1996020184A1 (en) 1994-12-23 1995-06-02 Naphthyl-benzoxazepines or -benzothiazepines as squalene synthetase inhibitors

Publications (1)

Publication Number Publication Date
BG100248A true BG100248A (bg) 1996-07-31

Family

ID=23427229

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100248A BG100248A (bg) 1994-12-23 1995-12-21 Инхибитори на скваленсинтетаза

Country Status (26)

Country Link
US (1) US5770594A (bg)
JP (1) JPH10500702A (bg)
KR (1) KR960022510A (bg)
CN (1) CN1133287A (bg)
AU (1) AU4067795A (bg)
BG (1) BG100248A (bg)
BR (1) BR9505995A (bg)
CA (1) CA2207772A1 (bg)
CZ (1) CZ344795A3 (bg)
FI (1) FI972696A0 (bg)
GT (1) GT199500058A (bg)
HU (1) HUT74672A (bg)
IL (1) IL116399A0 (bg)
IS (1) IS4312A (bg)
LV (1) LV11325B (bg)
MA (1) MA23746A1 (bg)
MX (1) MX9704683A (bg)
NO (1) NO955288L (bg)
OA (1) OA10204A (bg)
PE (1) PE60096A1 (bg)
PL (1) PL311997A1 (bg)
SI (1) SI9500393A (bg)
SK (1) SK158795A3 (bg)
TN (1) TNSN95133A1 (bg)
TR (1) TR199501644A2 (bg)
WO (1) WO1996020184A1 (bg)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048701A1 (en) * 1996-06-20 1997-12-24 Pfizer Inc. 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
US5965553A (en) * 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US8679534B2 (en) * 1997-12-12 2014-03-25 Andrx Labs, Llc HMG-CoA reductase inhibitor extended release formulation
US6403576B1 (en) * 1998-08-24 2002-06-11 The United States Of America As Represented By The Secretary Of The Navy Antifungal and antiparasitic compounds
US20020054871A1 (en) * 1999-04-12 2002-05-09 Yadong Huang Methods and compositions for use in the treatment of hyperlipidemia
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
NZ518822A (en) * 1999-11-04 2004-12-24 Andrx Corp Treating a mammal with an APP processing disorder such as Alzheimer's Disease and Down's Syndrome by administering at least one HMG-CoA reductase inhibitor
ES2328225T3 (es) 2000-11-21 2009-11-11 Janssen Pharmaceutica Nv Derivados benzoheterociclicos inhibidores de la farnesil-transferasa.
WO2008121602A1 (en) * 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
GB0803747D0 (en) * 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48855A1 (en) * 1992-04-20 1998-05-18 Takeda Chemical Industries Ltd 4,1-benzoxazepin derivatives and their use
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
MX9702175A (es) * 1994-09-20 1997-06-28 Pfizer Combinacion de un inhibidor de absorcion de colesterol y un inhibidor de sintesis de colesterol.

Also Published As

Publication number Publication date
WO1996020184A1 (en) 1996-07-04
IS4312A (is) 1996-06-24
CA2207772A1 (en) 1996-07-04
PE60096A1 (es) 1996-12-28
KR960022510A (ko) 1996-07-18
NO955288D0 (no) 1995-12-22
NO955288L (no) 1996-06-24
FI972696A (fi) 1997-06-23
SI9500393A (en) 1997-04-30
US5770594A (en) 1998-06-23
FI972696A0 (fi) 1997-06-23
MA23746A1 (fr) 1996-07-01
SK158795A3 (en) 1997-01-08
IL116399A0 (en) 1996-03-31
LV11325A (lv) 1996-06-20
TNSN95133A1 (fr) 1996-02-06
CN1133287A (zh) 1996-10-16
MX9704683A (es) 1997-09-30
LV11325B (en) 1997-02-20
PL311997A1 (en) 1996-06-24
CZ344795A3 (en) 1996-09-11
HU9503783D0 (en) 1996-04-29
TR199501644A2 (tr) 1996-11-21
JPH10500702A (ja) 1998-01-20
GT199500058A (es) 1997-06-05
HUT74672A (en) 1997-01-28
AU4067795A (en) 1996-07-04
BR9505995A (pt) 1997-12-23
OA10204A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
YU15299A (sh) Farmaceutski sastavi
AU2401697A (en) 4,1-benzoxazepines or 4,1-benzothiazepines and their use as squalene synthetase inhibitors
GR3026758T3 (en) Lactobacillus strains of human origin, their compositions and uses thereof
MX9800625A (es) Marcfortinas y paraherquamidas antiparasitarias.
HUT68689A (en) Alpha-heteroaryloxymethyl-ketones as interleukin-1-beta converting enzyme inhibitors, pharmaceutical compositions containing them, process for producing them and the compositions
BG101139A (bg) Съдържащи хетероатоми циклопентанопиридилоксазолидинони
EP0650370A4 (en) METHODS AND COMPOSITIONS TARGETED ON SPECIFIC TISSUES.
EP0973540A4 (en) INSULATION AND STRUCTURAL ENLARGEMENT OF THE CRYOSTATIC LINEAR AND CYCLO DEPSIPEPTIDE DOLASTATIN 16, DOLASTATIN 17, AND DOLASTATIN 18
PL331900A1 (en) 1,4-heterocyclic inhibitors of metaloprotease
BG104943A (bg) Биоразпадащи се алгинатни гелове с постоянно отделяне
PL331838A1 (en) 1,3-diheterocyclic inhibitors of metaloproteases
MX9700557A (es) Dihidrobenzofuranos.
EP0765916A3 (en) Hydrosilylation crosslinkable compositions
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
HUP0104768A3 (en) 4-amino-3-oxo-azepanes as protease inhibitors and pharmaceutical compositions containing the same
ZA9710098B (en) Halogenopyrimidines.
BG103914A (bg) Фармацевтичен състав с продължително освобождаване и неговото използаве
EP0840606A4 (bg)
IL109720A (en) N-alkylthio polyamine derivatives and radioprotective compositions containing them
AU640520B2 (en) Novel squalene synthetase inhibitors
BG100248A (bg) Инхибитори на скваленсинтетаза
ZA97188B (en) Disinfecting compositions and processes for disinfecting surfaces.
EP0858262A4 (en) THROMBIN INHIBITORS
PL331882A1 (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofurane amines and 2-amino cyclohepta[b]benzofuranes
AU6849198A (en) Neurotrypsin